# Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Source: https://onco.cc/trials/nct02503423/  
OnCo record `nct02503423` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ASTX660 in non-Hodgkin lymphoma, run by Taiho Oncology, Inc., active and no longer recruiting.

## Summary

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas is a phase 1/2 interventional study registered as NCT02503423 by Taiho Oncology, Inc., with 253 participants enrolled, started 2015-07-14 and due to reach its primary completion in 2022-10. Interventions recorded: ASTX660.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02503423
- Phase: 1/2
- Setting: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
- Sponsor: Taiho Oncology, Inc.
- Enrolled: 253

## Sources

- ClinicalTrials.gov NCT02503423: https://clinicaltrials.gov/study/NCT02503423

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Araris Biotech (Taiho)](https://onco.cc/companies/araris/)

---
JSON: https://onco.cc/api/v1/entities/nct02503423.json